A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer

Name: A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer
Published: 2024
License: Public Domain

Hookipa Biotech GmbH · 2024

ClinicalTrials.gov · Datasets · License: Public Domain · 2024

Open Source ↗

head-and-neck-cancer hpv immune-checkpoint-inhibitor immunotherapy

oropharyngeal squamous cell carcinoma recurrent, head and neck cancer, squamous cell cancer, head and neck squamous cell carcinoma, hnscc, oropharyngeal squamous cell carcinoma, human papillomavirus 16, hpv, programmed cell death 1 ligand 1, pd-l1, immune checkpoint inhibitor, immunotherapy

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 993319
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.